GT Biopharma Inc(GTBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:08 PM ET (Korea 10/31 06:08)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -90.07 | Insider Own | 16% | Shs Outstand | 1.8M | Perf Week | -2.56% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 25.58% | Insider Trans | - | Shs Float | 1.7M | Perf Month | -14.19% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -2.5 | Inst Own | 5.2% | Short Float | 16.12% | Perf Quarter | -31.04% |
| Income | -0.03B | P/S | - | EPS this Y | 93.56% | Inst Trans | 10.74% | Short Ratio | 4.33 | Perf Half Y | -38.03% |
| Sales | 0.00B | P/B | 2.66 | EPS next 5Y | 65.26% | ROA | -342.05% | Short Interest | 0.28M | Perf YTD | -72.9% |
| Book/sh | 2 | P/C | 2.17 | EPS past 3/5Y | 31.76% 49.68% | ROE | -1446.48% | 52W High | -81.5% ($28.75) | Perf Year | -66.11% |
| Cash/sh | 2.45 | P/FCF | - | Sales past 3/5Y | - | ROIC | -618.74% | 52W Low | 8.35% ($4.91) | Perf 3Y | -97.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.09% | Gross Margin | - | Volatility(W/M) | 8.4% 10.03% | Perf 5Y | -99.89% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.66 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | EPS Q/Q | 98.92% | Profit Margin | - | RSI (14) | 41.34 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.38 | Sales Q/Q | - | SMA20 | -13.31% ($6.14) | Beta | 0.86 | Target Price | $75 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | -21.28% ($6.76) | Rel Volume | 0.31 | Prev Close | $5.6 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -50% - | SMA200 | -45.41% ($9.75) | Avg Volume(3M) | 0.06M | Price | $5.32 |
| IPO | 1980/3/17 | Option/Short | No/Yes | Trades | 203 | Volume | 20,071 | Change | -5% |
This is a US-based clinical-stage biotech developing the 'TriKE' platform for cancer immunotherapy using natural killer (NK) cells. Its lead candidate, GTB-3650, is a second-generation trispecific antibody designed to activate NK cells in patients with CD33-positive hematologic cancers to attack cancer cells. The company is also developing GTB-5550 for solid tumors and is a micro-cap Nasdaq-listed company.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 31% of its average volume.
GTBP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +93.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #498 of 595 in the industry
Based on market cap of $11M.
FAQ
What kind of company is GTBP?
GTBP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GTBP?
The market cap of GTBP is approximately $11M, ranking 5,399 within its sector.
What is the 52-week high and low for GTBP?
GTBP has recorded a 52-week high of $28.75 and a low of $4.91.
